Aurobindo Pharma Shares in Focus as April 17 Marks Buyback Record Date

Shares of Aurobindo Pharma Limited are drawing attention on April 17, 2026, as the stock turns ex-trade in line with its announced buyback. The company has fixed this date to identify eligible shareholders for participation in the repurchase programme.

Aurobindo Pharma Buyback Details

Aurobindo Pharma Limited plans to buy back up to 54,23,728 fully paid-up equity shares, representing nearly 0.93% of its total equity base.

The buyback price has been set at ₹1,475 per share, aggregating to a total consideration of ₹800 crore.

Aurobindo Pharma Record Date and Eligibility

April 17, 2026 has been designated as the record date to determine the entitlement of shareholders eligible to participate in the buyback.

Only those shareholders whose names appear on the company’s records as of this date will be able to tender their shares.

Aurobindo Pharma Mode of Buyback

The repurchase will be carried out via the tender offer route, allowing participation from all shareholders, including promoters and promoter group entities, on a proportionate basis.

Aurobindo Pharma Share Price Performance

As of April 17, 2026 at 12:30 PM, shares of Aurobindo Pharma Limited were trading at ₹1,384.80, down ₹1.70 or 0.12% from the previous close of ₹1,386.50.

Read More: Paytm Increases Stake in First Games to 82.6%, Approves ₹90 Crore Default Loss Guarantee.

Conclusion

With the record date falling today, Aurobindo Pharma Limited is likely to remain in focus as investors assess participation in the buyback and its potential impact on the stock.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.